ATLASATLAS fair value
$54.56
Close to fair value · 7% discount
Range: $49–$60Fair valuePrice
Travere Therapeutics (TVTX)
Travere Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$50.88▲ +1.82%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Travere Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Travere Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Travere Therapeutics's fair value at about $54.56 per share (reasonable range: $49.10 to $60.01). At $50.88, the stock trades within 8% of that figure: close to fair value.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Travere Therapeutics a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $46.78 and $54.98; in 9 out of 10, between $40.54 and $63.44. Estimated annual volatility is 42%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $5.5B
- 52-week high
- $68.73
- 52-week low
- $22.59
- Revenue (12 months)
- $591M
- Revenue growth (YoY)
- +110.5%
- Gross margin
- 97.9%
- Operating margin
- -12.8%
- Net margin
- -5.2%
- Return on equity
- -236.4%
- Free cash flow (12 months)
- $-18.3M
- Beta
- 1.06
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Travere Therapeutics sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks TVTX has traded between $22.59 and $68.73. Today it is 26.0% below that high and 125% above its low.
On the business: revenue grew 110.5% year over year; net margin is 5.2%.
Its beta is 1.06: it moves roughly in line with the market.
About the company
Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases.
Want to see everything about Travere Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Travere Therapeutics (TVTX) fair value?
About $54.56 per share according to ATLAS (reasonable range: $49.10 to $60.01). With the stock at $50.88, it is close to that value.
What is the chance TVTX goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, TVTX ends the month between $46.78 and $54.98.
How big is Travere Therapeutics and what is its P/E ratio?
Travere Therapeutics's market capitalization is $5.5B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is TVTX?
ATLAS estimates annual volatility at 42%. In a typical month, half of the outcomes end between $46.78 and $54.98.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer